Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25706923 | 0.84 | MEN1 (0.38) | MEN1KMT2AALDH1A1CHRM2CHRM1 | |
| SCHEMBL18259376 | 0.83 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1TSHRHCAR2 | |
| SCHEMBL18259497 | 0.83 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1TSHRHCAR2 | |
| SCHEMBL18259375 | 0.83 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1TSHRHCAR2 | |
| SCHEMBL22009220 | 0.83 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1TSHRHCAR2 | |
| SCHEMBL820844 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL375388 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL375387 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL14303234 | 0.81 | CHRM2 (0.38) | MEN1KMT2AALDH1A1CHRM2CHRM1 | |
| SCHEMBL21413792 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1TSHRHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008014263-A2 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | MEN1 1628/4885KMT2A 3244/4885ALDH1A1 4403/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | MEN1 1940/4885KMT2A 4487/4885ALDH1A1 4283/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | MEN1 1589/4885KMT2A 3092/4885ALDH1A1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.